Your browser is no longer supported. Please, upgrade your browser.
Settings
BTX [AMEX]
Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-3.04 Insider Own8.10% Shs Outstand1.48M Perf Week-1.46%
Market Cap1.23B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month609.88%
Income-4.40M PEG- EPS next Q- Inst Own0.20% Short Float- Perf Quarter313.53%
Sales5.80M P/S211.96 EPS this Y-110.90% Inst Trans- Short Ratio0.14 Perf Half Y1096.94%
Book/sh0.58 P/B74.29 EPS next Y- ROA-66.60% Target Price- Perf Year1806.64%
Cash/sh0.03 P/C1536.70 EPS next 5Y- ROE-248.90% 52W Range1.88 - 80.67 Perf YTD861.83%
Dividend- P/FCF- EPS past 5Y17.40% ROI-217.30% 52W High-46.58% Beta3.82
Dividend %- Quick Ratio0.70 Sales past 5Y-25.00% Gross Margin49.90% 52W Low2192.02% ATR10.47
Employees22 Current Ratio0.70 Sales Q/Q-76.90% Oper. Margin- RSI (14)59.42 Volatility46.37% 42.26%
OptionableNo Debt/Eq2.22 EPS Q/Q122.50% Profit Margin-76.40% Rel Volume1.34 Prev Close55.19
ShortableNo LT Debt/Eq0.56 Earnings- Payout- Avg Volume5.21M Price43.09
Recom2.00 SMA20110.53% SMA50257.83% SMA200546.77% Volume3,030,178 Change-21.92%
Apr-29-21 07:30AM  
Apr-26-21 07:30AM  
Apr-19-21 04:10PM  
Apr-15-21 04:10PM  
08:00AM  
Apr-06-21 08:00AM  
Mar-25-21 05:20PM  
Dec-14-20 08:44AM  
Nov-04-20 06:05PM  
May-08-20 10:37PM  
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.